MedTrace Logo

Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions

NCT00764777 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 325

Last updated 2013-01-25

No results posted yet for this study

Summary

The BRAVISSIMO trial wants to investigate in a controlled setting, the long-term (up to 24 months) outcome of the self-expanding nitinol Absolute Pro (Abbott Vascular) and the balloon-expandable Omnilink Elite (Abbott Vascular) stent in TASC A\&B and TASC C\&D iliac lesions. A separate analysis of both patient populations will be performed and listed.

Conditions

  • Peripheral Vascular Disease
  • Intermittent Claudication
  • Critical Limb Ischemia

Interventions

DEVICE

iliac stenting

Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents

Sponsors & Collaborators

  • Flanders Medical Research Program

    lead NETWORK

Principal Investigators

  • Marc Bosiers, MD · AZ Sint-Blasius, Dendermonde, Belgium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-09-30
Completion
2012-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00764777 on ClinicalTrials.gov